In addition to conventional cytogenetics, a common mutational status that defines AML mutations such as CEBPA, NPM1, and FLT3-ITD has been used extensively in clinical practice to determine prognoses and guide treatment approaches. This evidence concerns the gene NPM1 and acute myeloid leukemia.